Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Patients who required erythropoietin-stimulating agent (ESA) medication used epoetin beta.Characteristics of HD patients.Variables tested in both groupsPatients genotyped for PON1 SNVs (n = 1407)Patients tested for PON1 activity (n = 93)P-valueaVariables tested in one groupPatients tested for PON1 activity (n = 93)Clinical dataClinical and laboratory dataMale sex (n, %)782 (55.6%)55 (59.1%)0.520Living in the rural area (n, %)27 (29.0)Age (years)67.0 (11.9 to 96.1)66.7 (18.3 to 86.2)0.231LF-HD (n, %)78 (83.9%)RRT duration (years)5.8 (0.01 to 34.0)3.9 (0.2 to 22.3)0.00003Mean arterial pressure (mmHg)113.3 (60 to 166.7)Diabetic nephropathy (n, %)405 (28.8%)19 (20.4%)0.096Cigarette smoking (n, %)9 (9.7%)Coronary heart disease (n, %)542 (38.5% of 1406)25 (26.9%)0.027Urine output (mL/day)600 (0 to 2100)Myocardial infarction (n, %)299 (21.3% of 1406)15 (16.1%)0.292Treatment with antihypertensive drugs (n, %)43 (46.2%)Ischemic cerebral stroke (n, %)256 (19.2%) of 13359 (9.7)0.026Treatment with phosphate binding agents (n, %)79 (84.9%)Dry body mass (kg), n = 123571.5 (31.0 to 196.0)81.0 (44.4 to 144.0)0.000001Treatment with vitamin D or vitamin D analogs (n, %)7 (7.5%)Body mass index (kg/m2)b25.5 (14.3 to 59.2) n = 123026.7 (17.8 to 51.0)0.010Parathyroidectomy (n, %)1 (1.1%)Lipid-modifying treatment (n, %)statins (n, %)fibrates (n, %)statins and fibrates (n, %)ezetimibe (n, %)statins + ezetimibe (n, %)582 (44.3% of 1314)533 (91.6% of 582)36 (6.2% of 582)10 (1.7% of 582)1 (0.2% of 582)2 (0.3% of 582)24 (25.8% of 93)23 (95.8% of 24)1 (4.2% of 24)0000.00020.7121.0001.0001.0001.000Treatment with ESA (n, %)66 (71.0)ESA dose (µg/kg/week)90 (0 to 530)Type of dyslipidaemia by K/DOQIHemoglobin (g/dL)11.4 ± 1.3Hyper-LDL-cholesterolemic (n, %)388 of 1264 (30.7% )39 of 93 (41.9%)0.028Treatment with cinacalcet (n, %)6 (6.5%)Hyper-TG/hyper-non-HDL-cholesterolemic (n, %)79 of 1264 (6.2% )5 of 93 (5.4%)1.000Vitamin C supplementation (n, %)2 (2.2%)Mixed (n, %)186 of 1264 (14.7% )14 of 93 (15.1%)0.545Zinc supplementation (n, %)3 (3.2%)Non-dyslipidemic (n, %)610 of 1264 (48.3% )35 of 93 (37.6%)0.053Green tea intake (n, %)4 (4.3%)Atherogenic dyslipidaemia (n, %)459 of 1264 (36.3% )39 of 93 (41.9%)0.316PON1 activity (U/L)101.0 (27.7 to 212.9)Laboratory dataPON1/HDL-cholesterol ratio2.27 (0.57 to 7.10)Total cholesterol (mg/dL)170.2 (51 to 626)183 (83 to 626)0.170Creatinine (mg/dL)5.7 (1.9 to 14.4)HDL-cholesterol (mg/dL)40 (5 to 146.8)44.4 ± 11.70.044Urea (mg/dL)106 (41 to 270)LDL-cholesterol (mg/dL)95.9 (13.3 to 512)104 (35 to 512)0.012C-reactive protein (mg/L)4.3 (0.3 to 79.3)TG (mg/dL)146.4 (29.8 to 1363)157 (65 to 460)0.291Albumin (mg/dL)4.1 (2.6 to 4.7)Non-HDL-cholesterol (mg/dL)128 (8 to 593)135 (41 to 593)0.346Total calcium (mg/dL)8.8 (6.8 to 12.5)LDL/HDL cholesterol ratio2.38 (0.21 to 15.52)2.35 (0.680 to 15.52)0.699Phosphorus (mg/dL)4.85 (2.32 to 10.52)HDL/TC ratio0.249 (0.045 to 0.906)0.250 (0.053 to 0.530)0.430Total ALP (IU/L)93 (24 to 321)TG/HDL-cholesterol ratio3.60 (0.44 to 49.71)3.42 (1.06 to 17.04)0.717Parathyroid hormone (pg/mL)280 (7.3 to 1783.8)ALP alkaline phosphatase, ESA erythropoietin-stimulating agent, HD haemodialysis, HDL high-density lipoprotein, K/DOQI Kidney Disease Outcomes Quality Initiative, LDL low-density lipoprotein, LF-HD low-flux haemodialysis, NA not available in all patients, PON1 paraoxonase 1, PON1 paraoxonase 1 gene, SNV single nucleotide variant, RRT renal replacement therapy, TG triglyceride.aThe Kruskal: Wallis and Mann: Whitney U tests were used for comparison of continuous variables.

Source: Patent characteristics. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Patients were dialyzed in May: June 2019, three times a week.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Paraoxonase 1 concerning dyslipidaemia, cardiovascular diseases, and mortality in haemodialysis patients

Study design awaiting verification · Scientific Reports · 2021

Original publication title

Paraoxonase 1 concerning dyslipidaemia, cardiovascular diseases, and mortality in haemodialysis patients

Alicja E. Grzegorzewska; Paulina Adamska; Ewa Iwańczyk-Skalska; Kamila Ostromecka; Leszek Niepolski; Wojciech Marcinkowski; Adrianna Mostowska; Wojciech Warchoł; Czesław Żaba; Paweł P. Jagodziński

© The Author(s) 2021

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

Paraoxonase 1 (PON1) is known for preventing atherosclerosis through lipid-modifying features, antioxidant activity, anti-inflammatory, anti-apoptosis, anti-thrombosis, and anti-adhesion properties. Uremic patients requiring haemodialysis (HD) are especially prone to atherosclerosis and its complications. We analysed the PON1 gene (PON1) polymorphisms and serum PON1 (paraoxonase) activity concerning dyslipidaemia and related cardiovascular diseases and mortality to show how they associate under uremic conditions modified by maintenance HD treatment. The rs662 AA + AG (OR 1.76, 95%CI 1.10 to 2.80, P = 0.018), rs854560 TT (OR 1.48, 95%CI 1.04 to 2.11, P = 0.031), and rs854560 AT + TT (OR 1.28, 95%CI 1.01 to 1.63, P = 0.040) contributed to the prevalence of atherogenic dyslipidaemia diagnosed by the triglyceride (TG)/HDL-cholesterol ratio ≥ 3.8.

The normalized serum PON1 activity positively correlated with atherogenic dyslipidaemia (ẞ 0.67 ± 0.25, P = 0.008). The PON1 rs854560 allele T was involved in the higher prevalence of ischemic cerebral stroke (OR 1.38, 1.02 to 1.85, P = 0.034). The PON1 rs705379 TT genotype contributed to cardiovascular (HR 1.27, 95% CI 1.03 to 1.57, P = 0.025) and cardiac (HR 1.34, 95% CI 1.05 to 1.71, P = 0.018) mortality. All P-values were obtained in multiple regression analyses, including clinical variables. Multifaceted associations of PON1 with dyslipidaemia, ischemic cerebral stroke, and cardiovascular mortality in HD patients provide arguments for the consideration of PON1 and its protein product as therapeutic targets in the prevention of atherosclerosis and its complications in uremic patients.

Authors’ abstract

Paraoxonase 1 (PON1) is known for preventing atherosclerosis through lipid-modifying features, antioxidant activity, anti-inflammatory, anti-apoptosis, anti-thrombosis, and anti-adhesion properties. Uremic patients requiring haemodialysis (HD) are especially prone to atherosclerosis and its complications. We analysed the PON1 gene (PON1) polymorphisms and serum PON1 (paraoxonase) activity concerning dyslipidaemia and related cardiovascular diseases and mortality to show how they associate under uremic conditions modified by maintenance HD treatment. The rs662 AA + AG (OR 1.76, 95%CI 1.10 to 2.80, P = 0.018), rs854560 TT (OR 1.48, 95%CI 1.04 to 2.11, P = 0.031), and rs854560 AT + TT (OR 1.28, 95%CI 1.01 to 1.63, P = 0.040) contributed to the prevalence of atherogenic dyslipidaemia diagnosed by the triglyceride (TG)/HDL-cholesterol ratio ≥ 3.8.

The normalized serum PON1 activity positively correlated with atherogenic dyslipidaemia (ẞ 0.67 ± 0.25, P = 0.008). The PON1 rs854560 allele T was involved in the higher prevalence of ischemic cerebral stroke (OR 1.38, 1.02 to 1.85, P = 0.034). The PON1 rs705379 TT genotype contributed to cardiovascular (HR 1.27, 95% CI 1.03 to 1.57, P = 0.025) and cardiac (HR 1.34, 95% CI 1.05 to 1.71, P = 0.018) mortality. All P-values were obtained in multiple regression analyses, including clinical variables. Multifaceted associations of PON1 with dyslipidaemia, ischemic cerebral stroke, and cardiovascular mortality in HD patients provide arguments for the consideration of PON1 and its protein product as therapeutic targets in the prevention of atherosclerosis and its complications in uremic patients.

Publication and source details

Original title: Paraoxonase 1 concerning dyslipidaemia, cardiovascular diseases, and mortality in haemodialysis patients

Alicja E. Grzegorzewska; Paulina Adamska; Ewa Iwańczyk-Skalska; Kamila Ostromecka; Leszek Niepolski; Wojciech Marcinkowski; Adrianna Mostowska; Wojciech Warchoł; Czesław Żaba; Paweł P. Jagodziński

Scientific Reports · 2021

© The Author(s) 2021https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.http://dx.doi.org/10.13039/501100010438Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu502-01-02225363-03679502-01-01124182-07474504-01-11281910-7/108-05934502-01-01124182-07474Grzegorzewska Alicja E. Mostowska Adrianna Żaba Czesław Jagodziński Paweł P.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-12T13:13:21.116615+00:00

DOI: 10.1038/s41598-021-86231-0 · PMC7990965